



Mundipharma at a glance



\$1.8bn USD
in Sales



Headquartered in Cambridge UK, with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.



Global leader in Pain Management.
Global Consumer Health portfolio.



Pipeline includes *rezafungin* in Phase III and *tinostamustine* in Phase I/II clinical development.



Over 2800
employees

Capabilities across Commercial, Market Access, Manufacturing and Supply Chain.

Partner of choice to commercialise Specialty Care products (outside US).

Clear business model based on Commercial Excellence.



3500+
3300+

3,500+ Marketing Authorisations

Experience in late-phase development and in leading global, multi-centre clinical trials in Specialty Care.

Therapy areas include anti-infectives, biosimilars, central nervous system (CNS), diabetes, oncology, ophthalmology and respiratory.